scispace - formally typeset
R

Renato Mantegazza

Researcher at Carlo Besta Neurological Institute

Publications -  331
Citations -  11716

Renato Mantegazza is an academic researcher from Carlo Besta Neurological Institute. The author has contributed to research in topics: Myasthenia gravis & Medicine. The author has an hindex of 55, co-authored 286 publications receiving 9843 citations. Previous affiliations of Renato Mantegazza include University of Milan & Weizmann Institute of Science.

Papers
More filters
Journal ArticleDOI

Pathogenesis, diagnosis and treatment of Rasmussen encephalitis A European consensus statement

Christian G. Bien, +10 more
- 02 Feb 2005 - 
TL;DR: This work proposes formal diagnostic criteria and a therapeutic pathway for the management of RE patients, and summarizes recent data on the pathogenesis, clinical and paraclinical presentation, and therapeutic approaches.
Journal ArticleDOI

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis

Ezio Gerdoni, +10 more
- 01 Mar 2007 - 
TL;DR: To evaluate the ability of mesenchymal stem cells (MSCs), a subset of adult stem cells from bone marrow, to cure experimental autoimmune encephalomyelitis.
Journal ArticleDOI

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, +623 more
- 01 Dec 2017 - 
TL;DR: A phase 3, randomised, double-blind, placebo-controlled, multicentre study in 76 hospitals and specialised clinics across North America, Latin America, Europe, and Asia to assess the efficacy and safety of eculizumab in patients with refractory myasthenia gravis.
Journal ArticleDOI

Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.

Pia Bernasconi, +8 more
- 01 Aug 1995 - 
TL;DR: expression of transforming growth factor-beta 1 in the early stages of Duchenne muscular dystrophy may be critical in initiating muscle fibrosis and antifibrosis treatment could slow progression of the disease, increasing the utility of gene therapy.
Journal ArticleDOI

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis

Donald B. Sanders, +9 more
- 05 Aug 2008 - 
TL;DR: Initiation of mycophenolate mofetil treatment was not superior to placebo in maintaining myasthenia gravis control during a 36-week schedule of prednisone tapering, but MMF was well tolerated and adverse events were consistent with previous studies.